Physician profile
Jackie Russo
NPI 1134643315
$3,825.59
in general payments reported to CMS, 2019-2025
15 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.62 · 2022: $290 · 2023: $588 · 2024: $1,496 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.93 |
| Education | $123.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,159.14 | 2022-2025 | Tremfya |
| Abbvie INC. | $798.88 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $484.40 | 2023-2025 | Dupixent |
| Pfizer INC. | $337.90 | 2022-2025 | |
| Genzyme Corporation | $206.85 | 2023-2025 | |
| Incyte Corporation | $159.55 | 2022-2025 | Opzelura |
| Amgen INC. | $156.02 | 2022-2024 | Otezla |
| Lilly USA, LLC | $109.31 | 2023-2024 | Taltz, Olumiant |
| Revance Therapeutics, INC. | $89.60 | 2025 | Daxi |
| Arcutis Biotherapeutics, INC. | $68.94 | 2024-2025 | Zoryve |
| Ucb, INC. | $65.84 | 2023-2024 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $60.06 | 2021-2025 | |
| Organogenesis INC. | $52.91 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $40.55 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $35.64 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.